The investigation of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma.
In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options for advanced renal cell carcinoma (RCC).
In this first part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, provides an overview of the treatment landscape for advanced renal cell carcinoma.
/PRNewswire/ Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to.